Acurx Pharmaceuticals, Inc. financial data

Symbol
ACXP on Nasdaq
Location
259 Liberty Avenue, Staten Island, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
Acurx Pharmaceuticals, LLC (to 6/23/2021)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 319 %
Debt-to-equity 69.5 % +138%
Return On Equity -371 % -102%
Return On Assets -103 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.2M shares +24.9%
Common Stock, Shares, Outstanding 16M shares +23%
Entity Public Float 27.9M USD -6.38%
Common Stock, Value, Issued 16K USD +23%
Weighted Average Number of Shares Outstanding, Basic 15.8M shares +29.9%
Weighted Average Number of Shares Outstanding, Diluted 15.8M shares +29.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.67M USD +15.5%
General and Administrative Expense 10.1M USD +36.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -16.7M USD -27.2%
Earnings Per Share, Basic -1.16 USD/shares -2.66%
Earnings Per Share, Diluted -1.16 USD/shares -2.66%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 7.16M USD -34.6%
Assets 6.58M USD
Employee-related Liabilities, Current 42.3K USD +17.9%
Liabilities, Current 3.15M USD +4.42%
Liabilities 3.15M USD +4.42%
Retained Earnings (Accumulated Deficit) -61.7M USD -37.2%
Stockholders' Equity Attributable to Parent 3.43M USD -44.9%
Liabilities and Equity 6.58M USD -28.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.06M USD -58.5%
Net Cash Provided by (Used in) Financing Activities 4.51M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 16M shares +23%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.45M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.36M USD -30.5%
Deferred Tax Assets, Valuation Allowance 11.9M USD +67.7%
Deferred Tax Assets, Gross 11.9M USD +67.7%
Deferred Tax Assets, Operating Loss Carryforwards 5.52M USD +64.2%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 65.1M USD +27.2%